The leukapheresis treatment market encompasses the medical and biopharmaceutical sector focused on using apheresis systems, disposables, and collection kits to extract white blood cells from a patient or donor. It serves clinical applications such as therapeutic leukoreduction for acute leukemias, stem cell transplantation, immunotherapies, and the collection of high-purity starting cell material (such as leukopaks) for cell and gene therapy (CGT) manufacturing, including CAR-T treatments, across hospitals, blood centers, and biotech research facilities.
The global leukapheresis market was valued at USD 83.3 billion in 2025 and USD 90.6 billion in 2026, and it is projected to reach USD 138.7 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.9%.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=20283148
The leukapheresis treatment market is primarily driven by the rising global incidence of hematologic malignancies like leukemia, growing demand for cell and gene therapies (such as CAR-T), expanding clinical trial activity, and increasing R&D investments in personalized medicine. However, market growth is heavily restrained by the high cost of therapeutic leukapheresis procedures and specialized leukopaks, alongside limited reimbursement policies and regulatory hurdles in developing regions. Lucrative opportunities lie in expanding research infrastructure and clinical trial networks across emerging economies in Asia-Pacific and Latin America, as well as advancing automated, continuous, and non-invasive cell collection technologies. Despite these prospects, the market faces key challenges, including a shortage of skilled apheresis technicians, high initial capital investment costs for advanced apheresis systems, and complex cold-chain logistical constraints for vein-to-vein therapy delivery.
Target customers in the leukapheresis treatment market include institutional healthcare buyers—such as hospitals, specialized cancer centers, blood centers, and academic research institutes—alongside biopharmaceutical companies and contract development and manufacturing organizations (CDMOs) focused on cell and gene therapies, as well as individual patients undergoing therapeutic leukocyte reduction for hematologic conditions like leukemia. Institutional buyers and biopharma clients prioritize high cell yields, purity, dosage precision, strict GMP compliance, and workflow automation to ensure patient safety and seamless integration into advanced immunotherapy pipelines (such as CAR-T therapies). Individual patients receiving therapeutic leukapheresis prefer safe, efficient, and comfortable procedures with minimal risks of procedural complications. Purchasing behaviors among institutional and biopharmaceutical buyers are driven by stringent regulatory clearance standards, clinical safety protocols, product quality assurance, and long-term supply agreements for automated apheresis equipment and single-use disposable kits.
Market entry, expansion, and profitability in the leukapheresis treatment market are heavily shaped by stringent regulatory standards, rapid technological advancements, and distinct economic pressures. Regulatory bodies enforce strict clearance pathways, blood banking standards, and donor safety protocols for apheresis devices and single-use disposable kits, which ensures high procedural safety but elevates compliance costs and lengthens commercialization timelines. Technologically, the landscape is rapidly evolving with automated whole-blood processing systems, micro-fluidic filtration, and integrated software platforms that improve cell collection yields and consistency—critical for downstream cell and gene therapies like CAR-T—requiring continuous R&D investment for market players to stay competitive. Economically, while the growing global prevalence of blood cancers and increasing demand for personalized medicine drive market expansion, profitability is constrained by high procedural and equipment acquisition costs, complex reimbursement environments, and limited adoption in resource-constrained developing regions.
The leukapheresis treatment market is undergoing a rapid transformation from traditional acute clinical collections toward an indispensable component of automated, GMP-compliant cell and gene therapy (CGT) workflows. Driven by the expansion of CAR-T, TCR-T, and NK-cell immunotherapies, key emerging trends include the widespread adoption of smart, software-driven apheresis systems, closed single-use sterile disposable sets, and automated whole-blood processing platforms that enhance collection purity, throughput, and contamination control. Additionally, the market is shifting toward decentralized collection networks, remote monitoring, and expanding applications beyond oncology into autoimmune disorders, organ transplantation, and allogeneic off-the-shelf cell therapies. These trends are evolving at a rapid pace, supported by high double-digit growth in CGT clinical trials and a projected high single-to-double-digit annual expansion in market demand, reflecting continuous technological innovation and accelerating commercialization of novel cellular immunotherapies.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=20283148
Technological innovations disrupting the leukapheresis treatment market are centered on automated blood processing systems, advanced cell separation platforms, and mobile collection technologies designed to optimize cell and gene therapy manufacturing. Significant traction is being gained by next-generation automated apheresis systems and continuous flow centrifuges—such as Terumo BCT’s Reveos and Spectra Optia systems and Haemonetics’ NexSys PCS—which utilize intelligent software and advanced sensor controls to streamline component separation, reduce procedure times, and enhance target cell purity. Furthermore, the market is being disrupted by buoyancy-activated microbubble selection technologies and microfluidic/membrane-based sorting platforms that automate mononuclear cell purification, replacing labor-intensive manual methods like Ficoll density gradients. Concurrently, innovations in mobile, decentralized leukapheresis units equipped with digital monitoring and cold-chain logistics are emerging to bypass traditional hospital bottlenecks, directly expanding patient and donor access for autologous and allogeneic CAR-T cell therapy workflows.
In the leukapheresis treatment market, short-term trends are driven by temporary spikes in demand for cell collections during localized clinical trial phases, brief surges in pandemic-related research applications, and initial hype surrounding unvalidated direct-to-consumer immune-boosting or wellness therapies. Conversely, long-term structural shifts are firmly anchored in the clinical maturation and commercial scaling of cell and gene therapies—such as CAR-T, TCR, and NK-cell immunotherapies—which mandate standardized, GMP-compliant leukocyte harvesting. These enduring transformations are further reinforced by the continuous shift toward automated, smart apheresis platforms with real-time digital monitoring, expanding specialized clinical networks in emerging regions, and the growing integration of leukapheresis into mainstream management of hematologic malignancies and autoimmune conditions.
Source:https://www.marketsandmarkets.com/Market-Reports/leukapheresis-market-20283148.html
